Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer
- PMID: 22388515
- DOI: 10.1158/1078-0432.CCR-11-0699
Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer
Abstract
The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) signaling axis plays an important role in normal organ, vascular, and skeletal development. Deregulation of FGFR signaling through genetic modification or overexpression of the receptors (or their ligands) has been observed in numerous tumor settings, whereas the FGF/FGFR axis also plays a key role in driving tumor angiogenesis. A growing body of preclinical data shows that inhibition of FGFR signaling can result in antiproliferative and/or proapoptotic effects, both in vitro and in vivo, thus confirming the validity of the FGF/FGFR axis as a potential therapeutic target. In the past, development of therapeutic approaches to target this axis has been hampered by our inability to develop FGFR-selective agents. With the advent of a number of new modalities for selectively inhibiting FGF/FGFR signaling, we are now in a unique position to test and validate clinically the many hypotheses that have been generated preclinically.
©2012 AACR.
Similar articles
-
The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis.Expert Opin Ther Targets. 2015;19(10):1361-77. doi: 10.1517/14728222.2015.1062475. Epub 2015 Jun 30. Expert Opin Ther Targets. 2015. PMID: 26125971 Review.
-
The role of fibroblast growth factors and their receptors in prostate cancer.Endocr Relat Cancer. 2004 Dec;11(4):709-24. doi: 10.1677/erc.1.00535. Endocr Relat Cancer. 2004. PMID: 15613447 Review.
-
Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives.Cancer Discov. 2013 Mar;3(3):264-79. doi: 10.1158/2159-8290.CD-12-0362. Epub 2013 Feb 15. Cancer Discov. 2013. PMID: 23418312 Review.
-
De-regulated FGF receptors as therapeutic targets in cancer.Pharmacol Ther. 2010 Jan;125(1):105-17. doi: 10.1016/j.pharmthera.2009.10.001. Epub 2009 Oct 27. Pharmacol Ther. 2010. PMID: 19874848 Review.
-
Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy.Clin Cancer Res. 2005 Apr 1;11(7):2702-12. doi: 10.1158/1078-0432.CCR-04-2057. Clin Cancer Res. 2005. PMID: 15814652
Cited by
-
Transcriptome Analysis Reveals Differentially Expressed circRNAs Associated with Fecundity in Small-Tail Han Sheep Thyroid with Different FecB Genotypes.Animals (Basel). 2023 Dec 27;14(1):105. doi: 10.3390/ani14010105. Animals (Basel). 2023. PMID: 38200837 Free PMC article.
-
Expression Profile of Fibroblast Growth Factor Receptors, Keratinocyte Differentiation Markers, and Epithelial Mesenchymal Transition-Related Genes in Actinic Keratosis: A Possible Predictive Factor for Malignant Progression?Biology (Basel). 2021 Apr 15;10(4):331. doi: 10.3390/biology10040331. Biology (Basel). 2021. PMID: 33920760 Free PMC article.
-
Antibody-mediated activation of FGFR1 induces FGF23 production and hypophosphatemia.PLoS One. 2013;8(2):e57322. doi: 10.1371/journal.pone.0057322. Epub 2013 Feb 22. PLoS One. 2013. PMID: 23451204 Free PMC article.
-
Design, Synthesis and Biological Evaluation of 6-(2,6-Dichloro-3,5-dimethoxyphenyl)-4-substituted-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors.Molecules. 2016 Oct 23;21(10):1407. doi: 10.3390/molecules21101407. Molecules. 2016. PMID: 27782099 Free PMC article.
-
Advanced Delivery Strategies of Nintedanib for Lung Disorders and Beyond: A Comprehensive Review.AAPS PharmSciTech. 2024 Jul 1;25(6):150. doi: 10.1208/s12249-024-02869-9. AAPS PharmSciTech. 2024. PMID: 38954161 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
